A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2011
At a glance
- Drugs Lanicemine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Nov 2007 Status changed from recruiting to completed.
- 17 Aug 2007 New trial record.